| ISIN | CH1205452688 |
|---|---|
| Valor Number | 120545268 |
| Bloomberg Global ID | |
| Fund Name | Bellevue Healthcare Strategy I2 EUR |
| Fund Provider |
Bellevue Asset Management AG
Zürich, Switzerland Phone: +41 44 267 67 00 E-Mail: info@bellevue.ch Web: www.bellevue.ch |
| Fund Provider | Bellevue Asset Management AG |
| Representative in Switzerland | |
| Distributor(s) |
Zürcher Kantonalbank Zürich Phone: +41 44 293 93 93 |
| Asset Class | Equities |
| EFC Category | |
| Distribution Policy | Accumulation |
| Home Country | Switzerland |
| Issuing Condition | Special conditions apply to the issue of units |
| Redemption Condition | Special conditions apply to the redemption of units |
| Investment Strategy *** | N/A |
| Peculiarities |
| Current Price * | 987.14 EUR | 14.10.2025 |
|---|---|---|
| Previous Price * | 997.17 EUR | 13.10.2025 |
| 52 Week High * | 1,082.50 EUR | 05.02.2025 |
| 52 Week Low * | 914.32 EUR | 07.04.2025 |
| NAV * | 987.14 EUR | 14.10.2025 |
| Issue Price * | ||
| Redemption Price * | ||
| Closing Price * | ||
| Indicative Minimum Price | ||
| Fund Assets *** | 61,707,398 | |
| Unit/Share Assets *** | 19,424,678 | |
| Trading Information SIX | ||
| YTD Performance | -3.83% |
31.12.2024 - 14.10.2025
31.12.2024 14.10.2025 |
|---|---|---|
| YTD Performance (in CHF) | -4.86% |
31.12.2024 - 14.10.2025
31.12.2024 14.10.2025 |
| 1 month | +2.41% |
15.09.2025 - 14.10.2025
15.09.2025 14.10.2025 |
| 3 months | +4.11% |
14.07.2025 - 14.10.2025
14.07.2025 14.10.2025 |
| 6 months | +6.41% |
14.04.2025 - 14.10.2025
14.04.2025 14.10.2025 |
| 1 year | -7.97% |
14.10.2024 - 14.10.2025
14.10.2024 14.10.2025 |
| 2 years | +0.47% |
16.10.2023 - 14.10.2025
16.10.2023 14.10.2025 |
| 3 years | -0.17% |
14.10.2022 - 14.10.2025
14.10.2022 14.10.2025 |
| 5 years | -1.03% |
06.10.2022 - 14.10.2025
06.10.2022 14.10.2025 |
| Equity Participation Rate in % | 86.13 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Share of Total Fund Assets in % | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Real Estate Rate in % | 0.00 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ADDI | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| ADDI Date | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Thermo Fisher Scientific Inc | 3.60% | |
|---|---|---|
| Galderma Group AG Registered Shares | 3.56% | |
| Sandoz Group AG Registered Shares | 3.38% | |
| UCB SA | 3.33% | |
| Eli Lilly and Co | 3.27% | |
| HCA Healthcare Inc | 3.21% | |
| AbbVie Inc | 3.20% | |
| McKesson Corp | 3.14% | |
| AstraZeneca PLC | 2.82% | |
| Boston Scientific Corp | 2.69% | |
| Last data update | 31.10.2025 | |
| TER | 0.61% |
|---|---|
| TER date | 30.09.2024 |
| Performance Fee *** | |
| PTR | |
| Max. Management Fee *** | 0.60% |
| Ongoing Charges *** | |
|
SRRI ***
|
|
| SRRI date *** | 30.09.2025 |